Division of Gastroenterohepatology, Department of Internal Medicine, School of Medicine, Universitas Syiah Kuala, Banda Aceh, Aceh, 23111, Indonesia.
Division of Gastroenterohepatology, Department of Internal Medicine, Dr. Zainoel Abidin Hospital, Banda Aceh, Aceh, 23126, Indonesia.
F1000Res. 2021 Apr 19;10:301. doi: 10.12688/f1000research.52216.1. eCollection 2021.
This study aimed to determine the cumulative prevalence of prolonged gastrointestinal (GI) symptoms, including nausea, vomiting, diarrhea, lack of appetite, abdominal pain, and dysgeusia, in survivors of both mild and severe COVID-19 worldwide and to discuss the potential pathogenesis. Three databases (PubMed, Scopus, and Web of Science) were searched for relevant articles up to January 30, 2021. Data on study characteristics, clinical characteristics during follow-up, the number of patients with prolonged GI symptoms, and total number of COVID-19 survivors were retrieved according to PRISMA guidelines. The quality of eligible studies was assessed using the Newcastle-Ottawa scale. The pooled prevalence of specific prolonged GI symptoms was calculated and the association between COVID-19 severity and the occurrence of prolonged GI symptoms was assessed if appropriate. The global prevalence of prolonged nausea was 3.23% (95% CI: 0.54%-16.53%) among 527 COVID-19 survivors. Vomiting persisted in 93 of 2,238 COVID-19 survivors (3.19%, 95% CI: 1.62%-6.17%) and prolonged diarrhea was found in 34 of 1,073 survivors (4.12%, 95% CI: 1.07%-14.64%). A total of 156 patients among 2,238 COVID-19 survivors (4.41%, 95% CI: 1.91%-9.94%) complained of persistent decreased or loss of appetite. The cumulative prevalence of prolonged abdominal pain was 1.68% (95% CI: 0.84%-3.32%), whereas persistent dysgeusia was identified in 130 cases among 1,887 COVID-19 survivors (7.04%, 95% CI: 5.96%-8.30%). Data was insufficient to assess the relationship between COVID-19 severity and the occurrence of all prolonged GI symptoms. Persistent GI symptoms among COVID-19 survivors after discharge or recovery raises a concern regarding the long-term impact of the COVID-19 infection on the quality of life of the survivors. Despite several potential explanations proposed, studies that aim to follow patients after recovery from COVID-19 and determine the pathogenesis of the prolonged symptoms of COVID-19 survivors are warranted. PROSPERO registration: CRD42021239187.
本研究旨在确定全球轻度和重度 COVID-19 幸存者中持续胃肠道（GI）症状（包括恶心、呕吐、腹泻、食欲不振、腹痛和味觉障碍）的累积患病率，并讨论其潜在发病机制。研究人员在 PubMed、Scopus 和 Web of Science 三个数据库中检索了截至 2021 年 1 月 30 日的相关文献。根据 PRISMA 指南，检索了研究特征、随访期间临床特征、持续胃肠道症状患者数量以及 COVID-19 幸存者总数等数据。使用纽卡斯尔-渥太华量表评估合格研究的质量。计算了特定持续胃肠道症状的合并患病率，并评估了 COVID-19 严重程度与持续胃肠道症状发生之间的关联（如果适用）。在 527 名 COVID-19 幸存者中，持续恶心的全球患病率为 3.23%（95%CI：0.54%-16.53%）。在 2238 名 COVID-19 幸存者中，有 93 名（3.19%，95%CI：1.62%-6.17%）持续呕吐，1073 名幸存者中有 34 名（4.12%，95%CI：1.07%-14.64%）持续腹泻。在 2238 名 COVID-19 幸存者中，共有 156 名（4.41%，95%CI：1.91%-9.94%）抱怨持续食欲减退或丧失。持续腹痛的累积患病率为 1.68%（95%CI：0.84%-3.32%），而在 1887 名 COVID-19 幸存者中，有 130 名（7.04%，95%CI：5.96%-8.30%）持续味觉障碍。目前尚无足够数据评估 COVID-19 严重程度与所有持续胃肠道症状发生之间的关系。COVID-19 幸存者出院或康复后持续出现胃肠道症状，这引起了人们对 COVID-19 感染对幸存者生活质量的长期影响的关注。尽管提出了一些潜在的解释，但有必要进行旨在跟踪 COVID-19 康复后患者并确定 COVID-19 幸存者持续症状发病机制的研究。PROSPERO 注册：CRD42021239187。
Clin Gastroenterol Hepatol. 2024-5
Therap Adv Gastroenterol. 2022-8-19
BMJ Open Gastroenterol. 2020-5
Front Cell Infect Microbiol. 2025-5-29
Front Cell Infect Microbiol. 2024
Medicina (Kaunas). 2023-9-24
Front Neurosci. 2023-9-15
Immun Inflamm Dis. 2023-9
Genes Dis. 2023-6-19
J Pediatr Gastroenterol Nutr. 2023-5-1
J Microbiol Immunol Infect. 2021-8
Clin Epidemiol Glob Health. 2021
Hum Vaccin Immunother. 2020-12-1
J Korean Med Sci. 2020-12-7
Open Forum Infect Dis. 2020-10-21
Zotero 插件
